Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus AMOXIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus AMOXIL.
AMOXICILLIN PEDIATRIC vs AMOXIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in CrCl <30 mL/min.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic